8:58AM Cumberland Pharma correction: David L. Lowranceas, co's CFO, will join Aucela Inc as Aucela's new CFO (CPIX) 5.12 : Acucela Inc announced that it has appointed David L. Lowrance as Chief Financial Officer. Lowrance is currently listed as Cumberland Pharma's VP and CFO. We previously noted Cumberland Pharma appointed David L. Lowranceas as CFO. Our 8:02 ET comment has been deleted.
Recent CPIX News
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 05/26/2026 10:00:54 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 09:02:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 09:07:03 PM
- CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE • PR Newswire (US) • 05/05/2026 09:00:00 PM
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE • PR Newswire (US) • 04/28/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 09:08:24 PM
- Cumberland Pharmaceuticals jumps on $100M Apotex transaction • IH Market News • 04/23/2026 02:52:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 01:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 01:01:32 PM
- Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex • PR Newswire (US) • 04/23/2026 01:00:00 PM
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 • PR Newswire (US) • 04/22/2026 12:00:00 PM
- CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE • PR Newswire (US) • 04/16/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:24:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:22:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:21:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:20:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:20:05 PM
- Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting • PR Newswire (US) • 03/17/2026 01:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/12/2026 09:00:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/09/2026 09:03:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 09:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 10:10:28 PM
- CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® • PR Newswire (US) • 02/25/2026 12:00:00 PM

